drugset / Trial / NCT03589027

Darunavir and Rilpivirine Interactions With Levonorgestrel Implant

NCT03589027

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the pharmacokinetic properties of Rilpivirine and Darunavir when used in combination with Levonorgestrel

Timeline

Start
2018-08-07
Primary completion
2019-06
Completion
2020-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Darunavir Small molecule 600 mg Oral
Subject Levonorgestrel Small molecule 150 mg Other
Subject Rilpivirine Small molecule 25 mg Oral
Background Ritonavir Other / unclassified 100 mg Oral